Name: SPRO Income Statement - Spero Therapeutics Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

SPRO - Spero Therapeutics, Inc.

USD | NASDAQ | Healthcare

SPRO Income Statement - Spero Therapeutics Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q3 FY 16
Revenues
Revenues	0.3	41.3	5.4	14.2	5.9	15.0	13.5	10.2	9.3	73.5	25.5	2.7	2.1	47.4	2.0	2.0

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Revenues
Revenues	61.2	66.8	48.0	103.8	53.5	18.3	9.3	18.1	4.0	2.0	0.3	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	27.8	38.5	96.8	51.4	47.6	64.5	67.0	65.8	33.9	32.9	26.3	11.1
Selling General & Administrative	-
Operating Income
Operating Income	13.5	6.3	(73.4)	21.5	(42.2)	(88.0)	(79.1)	(63.2)	(42.8)	(41.7)	(33.2)	(13.3)
Non-Operating
Interest Income	2.0	2.5	4.7	3.9	1.1	0.3	0.4	1.3	1.1	-	-	-
Interest Expense	-	-
Tax & Net
Income Tax Expense	-	0.3	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income From Continuing Ops	15.2
Per Share
EPS Basic	0.27	0.15	(1.27)	0.43	(1.23)	(2.91)	-	-	-	-	-	-
EPS Diluted	0.27	0.15
Supplementary Data
EBITDA	-	6.3	(73.4)	21.8	(41.3)	(87.3)	(78.4)	(62.5)	(42.4)	(41.4)	(32.9)	(13.3)
EBIT	13.5	6.3

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	2.9	5.6	8.6	10.7	13.6	28.8	26.9	23.7	17.3	16.6	16.4	9.5	9.0	15.1	7.4	8.2	17.0	17.2	14.4	14.5	18.4	13.2	17.7	15.7	20.4	25.7	18.5	12.0	9.5	9.1	8.5	7.4	8.9	12.5	6.9	7.5	6.0	6.0
Selling General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	4.9	4.3	4.2	5.9	6.8	7.1	5.2	5.5	5.9	6.4	5.7	6.1	7.3	6.5	6.6	8.1	15.3
Depreciation & Amortization	-	-	-	-	-	-	-	-	0.0	-	-	-	0.1	-	-	-	0.2
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	7.8	9.9	13.4	16.6	20.6	36.8	32.1	29.3	23.2	23.0	27.4	15.6	16.3	21.5	13.8	28.1

Operating Income
Operating Income	(7.5)	31.4	(7.9)	(2.4)	(14.7)	(21.7)	(18.6)	(19.1)	(14.0)	50.5	(1.9)	(12.9)	(14.2)	25.9	(11.8)	(26.1)	(30.2)	(27.5)	(22.5)	(18.5)	(19.4)	(18.8)	(19.0)	(18.5)	(22.8)	(25.9)	(18.0)	(13.7)	(5.7)	(11.1)	(10.9)	(10.0)	(10.8)	(14.0)	(10.0)	(10.2)	(7.6)	(7.9)

Tax & Net
Income Tax Expense	-	-	0.0	-	-	-	0.3	-	-	-	2.2	-	-	-	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	(7.2)	31.5	(7.4)	(1.7)	(13.9)	(20.9)	(17.1)	(17.9)	(12.7)	51.2	(3.2)	(11.9)	(13.3)	26.8	(11.7)	(28.7)	(32.8)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(7.2)	31.5	(7.4)	(1.7)	(13.9)	(20.9)	(17.1)	(17.9)	(12.7)	51.2	(3.2)	(11.9)	(13.3)	26.8	(11.7)	(28.7)	(32.8)
Net Income Attributable To Parent	(7.2)	31.5	(7.4)	(1.7)	(13.9)	(20.9)	(17.1)	(17.9)	(12.7)	51.2	(3.2)	(11.9)	(13.3)	26.8	(11.7)	(28.7)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(7.2)	31.5	(7.4)	(1.7)	(13.9)	(20.9)	(17.1)	(17.9)	(12.7)	51.2	(3.2)	(11.9)	(13.3)	119.6	(11.7)

Per Share
EPS Basic	(0.13)	-	(0.13)	(0.03)	(0.25)	-	(0.32)	(0.33)	(0.24)	-	(0.06)	(0.23)	(0.25)	-	(0.33)	(0.87)	(1.01)	-	(0.70)	(0.63)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Diluted	(0.13)	-	(0.13)	(0.03)	(0.25)	-	(0.32)	(0.33)	(0.24)	-	(0.06)	(0.23)	(0.25)	-	(0.33)	(0.87)	(1.01)	-
Shares Basic	57.3	-	56.3	56.0	55.4	-	54.1	54.0	53.5	-	52.7	52.6	52.5	-	35.9	33.0	32.6	-
Shares Diluted	57.3	-	56.3	56.0	55.4	-	54.1	54.0	53.5	-	52.7	52.6	52.5	-	35.9	33.0	32.6	-

Supplementary Data
EBITDA	-	-	-	-	-	-	-	-	(14.0)	-	-	-	(14.1)	-	-	-	(30.0)	-	-	-	(19.2)	-	-	-	(22.6)	-	-	-	(5.5)	-	-	-	(10.7)	-	-	-	(7.5)	-
EBIT	(7.5)	31.4	(7.9)	(2.4)	(14.7)	(21.7)	(18.6)	(19.1)	(14.0)	50.5	(1.9)	(12.9)	(14.2)	25.9	(11.8)	(26.1)	(30.2)	(27.5)	(22.5)